The Buchanan Ocular Therapeutics Unit (BOTU) aims to develop and translate ocular therapeutic related scientific research into the clinical setting, whether pharmaceutical, cell, or technology-based. Current research focusses on the evaluation of novel drug therapies for the treatment of sight-threatening diseases with an inflammatory component, as well as the development of novel preclinical models of such diseases. Moreover, we are investigating novel molecules and drug delivery systems that can be targeted specifically to diseased cells while also offering sustained drug release over time.
Find out more about our current projects below: